Certain blockbuster obesity drugs will be available for as little as $149 per month and more Medicare enrollees will have access to them under two deals announced Thursday by the Trump administration.

Telehealth for Medicare started during the pandemic and became popular quickly. But the shutdown put an abrupt halt to payments for the service.

Novo Nordisk and Eli Lilly reached deals to lower GLP-1 drug costs for Medicare and Medicaid patients under Trump’s new pricing initiative.

Medicare cover GLP-1s under a Trump-negotiated pricing plan starting in 2026, lowering costs for key obesity and diabetes drugs.

The Danish pharmaceutical giant Novo Nordisk has struck an agreement with the Centers for Medicare & Medicaid Services (CMS) to set a negotiated price for

Seniors could soon pay just $50 a month for Ozempic and other drugs used for weight loss under a new Trump plan to cut prescription costs.

Medicare has selected the technology vendors who'll run its prior authorization pilot in New Jersey, Ohio, Oklahoma, Texas, Arizona, and Washington

Medicare’s coverage of GLP-1 therapies is beginning to shift, and the implications for retirees could be significant. In this video, Bob Powell speaks with Jae Oh, author of Maximize Your Medicare, about what older adults and caregivers need to know as prices come down and eligibility expands.